Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad

Here's Why the Bad News About the Pfizer Vaccine Isn't So Bad
·4 min read

When we think of the Pfizer (NYSE: PFE) coronavirus vaccine, we think of strong performance. The company wowed the global health community when it reported overall efficacy of more than 90% in six-month follow up of its phase 3 clinical trial. Pfizer has fully vaccinated more than 86 million Americans and is the leading vaccine provider in other countries too -- such as Israel.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting